AEQUUS PHARMACEUTICALS INC(TSX-V:AQS) stock Fundamental Analysis

Fundamental Rating

We assign a fundamental rating of 0 out of 10 to AQS. AQS was compared to 34 industry peers in the Pharmaceuticals industry. AQS may be in some trouble as it scores bad on both profitability and health. AQS is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

AQS had negative earnings in the past year.

AQS had a negative operating cash flow in the past year.

AQS had negative earnings in each of the past 5 years.

In the past 5 years AQS always reported negative operating cash flow.

1.2 Ratios

AQS has a Return On Assets of -311.85%. This is amonst the worse of the industry: AQS underperforms 96.97% of its industry peers.

		Industry Rank	Sector Rank
ROA	-311.85%
ROE	N/A
ROIC	N/A

ROA(3y)-168.11%

ROA(5y)-144.68%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 53.45%, AQS is in the better half of the industry, outperforming 78.79% of the companies in the same industry.

AQS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	53.45%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

AQS does not have a ROIC to compare to the WACC, probably because it is not profitable.

AQS has about the same amout of shares outstanding than it did 1 year ago.

The number of shares outstanding for AQS has been increased compared to 5 years ago.

Compared to 1 year ago, AQS has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -67.10, we must say that AQS is in the distress zone and has some risk of bankruptcy.

The Altman-Z score of AQS (-67.10) is worse than 93.94% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-67.1

ROIC/WACCN/A

WACC2.26%

2.3 Liquidity

AQS has a Current Ratio of 0.05. This is a bad value and indicates that AQS is not financially healthy enough and could expect problems in meeting its short term obligations.

Looking at the Current ratio, with a value of 0.05, AQS is doing worse than 96.97% of the companies in the same industry.

AQS has a Quick Ratio of 0.05. This is a bad value and indicates that AQS is not financially healthy enough and could expect problems in meeting its short term obligations.

The Quick ratio of AQS (0.03) is worse than 96.97% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.05
Quick Ratio	0.03

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 18.14% over the past year.

Looking at the last year, AQS shows a very negative growth in Revenue. The Revenue has decreased by -29.63% in the last year.

AQS shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -28.97% yearly.

EPS 1Y (TTM)18.14%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%23.6%

Revenue 1Y (TTM)-29.63%

Revenue growth 3Y-53.85%

Revenue growth 5Y-28.97%

Sales Q2Q%1010.18%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AQS. In the last year negative earnings were reported.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for AQS!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

AEQUUS PHARMACEUTICALS INC

TSX-V:AQS (2/19/2025, 7:00:00 PM)

0.01

+0.01 (+100%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)11-27 2024-11-27

Earnings (Next)04-28 2025-04-28

Inst OwnersN/A

Inst Owner ChangeN/A

Ins Owners14.68%

Ins Owner ChangeN/A

Market Cap1.33M

Analysts0

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	3.21
P/FCF	N/A
P/OCF	N/A
P/B	N/A
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-0.02

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)-0.02

FCFYN/A

OCF(TTM)-0.02

OCFYN/A

SpS0

BVpS-0.05

TBVpS-0.05

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-311.85%
ROE	N/A
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	53.45%
FCFM	N/A

ROA(3y)-168.11%

ROA(5y)-144.68%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score1

Asset Turnover0.48

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.05
Quick Ratio	0.03
Altman-Z	-67.1

F-Score1

WACC2.26%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)18.14%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%23.6%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)-29.63%

Revenue growth 3Y-53.85%

Revenue growth 5Y-28.97%

Sales Q2Q%1010.18%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y3.65%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-29.21%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-25.57%

OCF growth 3YN/A

OCF growth 5YN/A

AEQUUS PHARMACEUTICALS INC (AQS.CA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens